U.S. Executive Action to Advance Ibogaine Research Signals Major Opportunity for Psyence BioMed
PBM has more than doubled off its 52-week low of $1.92 on elevated volume (51× avg).
Summary
Psyence BioMed (PBM) is welcoming anticipated U.S. executive action aimed at advancing research into ibogaine, a compound central to the company's therapeutic pipeline. This potential executive order would evaluate the safety and therapeutic potential of ibogaine, currently a Schedule I substance. For PBM, which highlights its global leadership in GMP ibogaine manufacturing and ethically sourced supply, this development is highly significant. It signals a potential shift towards a more favorable regulatory environment in the U.S., which could accelerate clinical research and future market opportunities for ibogaine-based therapies. This news follows PBM's recent expansion of its Australian clinical site network, indicating active development in the psychedelic space. Investors should monitor the specifics of the executive order and any subsequent regulatory changes that could impact PBM's ibogaine development programs.
At the time of this announcement, PBM was trading at $9.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6M. The 52-week trading range was $1.92 to $74.94. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.